The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Injectable HIV therapy offers hope for those who struggle with daily pills—providing a powerful, long-lasting alternative to ...

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...

Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily ...

HIV conference opened in San Francisco Sunday, March 9, under a cloud of uncertainty in the face of the Trump ...

Theratechnologies (THTX) presented data from a real-world, observational, registry study demonstrating the efficacy and safety of ibalizumab in ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

The Kingdom of Eswatini has the highest HIV/AIDS incidence in the world. However, the mission of the Piggs Peak Partnership ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...